DK0998556T3 - Diagnose og behandling af sygdomme ved anvendelse af anti- T-celle-receptor-Vbeta-antistoffer eller -peptider som genkendelse af antistofferne, og endokrint udskillelsesregulatorisk protein 1 (ESRP 1) - Google Patents
Diagnose og behandling af sygdomme ved anvendelse af anti- T-celle-receptor-Vbeta-antistoffer eller -peptider som genkendelse af antistofferne, og endokrint udskillelsesregulatorisk protein 1 (ESRP 1)Info
- Publication number
- DK0998556T3 DK0998556T3 DK98935160T DK98935160T DK0998556T3 DK 0998556 T3 DK0998556 T3 DK 0998556T3 DK 98935160 T DK98935160 T DK 98935160T DK 98935160 T DK98935160 T DK 98935160T DK 0998556 T3 DK0998556 T3 DK 0998556T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- diseases
- esrp
- peptides
- diagnosis
- Prior art date
Links
- 101500027988 Mus musculus ADGRV1 subunit beta Proteins 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002124 endocrine Effects 0.000 title 1
- 102000034356 gene-regulatory proteins Human genes 0.000 title 1
- 108091006104 gene-regulatory proteins Proteins 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 230000003248 secreting effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 230000003054 hormonal effect Effects 0.000 abstract 1
- 230000035879 hyperinsulinaemia Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 210000002955 secretory cell Anatomy 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Cardiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9715281A GB2327423B (en) | 1997-07-21 | 1997-07-21 | Ligands, including antibodies, showing reactivity against endocrine cells for use in therapy and diagnosis |
| GBGB9810676.8A GB9810676D0 (en) | 1998-05-18 | 1998-05-18 | Ligands including antibodies showing reactivity against endocrine cells for use in therapy and diagnosis |
| EP98935160A EP0998556B1 (en) | 1997-07-21 | 1998-07-20 | Diagnosis and treatment of diseases using anti-t-cell receptor vbeta antibodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein 1 (esrp1) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0998556T3 true DK0998556T3 (da) | 2005-10-17 |
Family
ID=26311906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK98935160T DK0998556T3 (da) | 1997-07-21 | 1998-07-20 | Diagnose og behandling af sygdomme ved anvendelse af anti- T-celle-receptor-Vbeta-antistoffer eller -peptider som genkendelse af antistofferne, og endokrint udskillelsesregulatorisk protein 1 (ESRP 1) |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US6689359B1 (da) |
| EP (2) | EP1595951A1 (da) |
| JP (1) | JP2002511765A (da) |
| KR (2) | KR100567277B1 (da) |
| CN (1) | CN1330754C (da) |
| AT (1) | ATE297983T1 (da) |
| AU (1) | AU758455B2 (da) |
| BR (1) | BR9810118A (da) |
| CA (1) | CA2296842C (da) |
| CU (1) | CU23412A3 (da) |
| DE (1) | DE69830588T2 (da) |
| DK (1) | DK0998556T3 (da) |
| EA (1) | EA003131B1 (da) |
| ES (1) | ES2245034T3 (da) |
| IL (3) | IL133277A0 (da) |
| NZ (1) | NZ501424A (da) |
| PL (1) | PL204503B1 (da) |
| PT (1) | PT998556E (da) |
| SI (1) | SI0998556T1 (da) |
| TR (1) | TR200000181T2 (da) |
| WO (1) | WO1999005175A2 (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003510049A (ja) * | 1999-09-23 | 2003-03-18 | ライジェル・ファーマシューティカルズ・インコーポレイテッド | Ｔｒａｆ４関連細胞周期タンパク質、組成物および使用法 |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| AU2012244244B2 (en) * | 2005-08-11 | 2015-08-27 | Arpi Matossian-Rogers | TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease |
| JP2009505640A (ja) * | 2005-08-11 | 2009-02-12 | − ロジャーズ、アルピ マトシアン | 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド |
| BRPI0619249A2 (pt) | 2005-11-30 | 2011-09-20 | Abbott Lab | anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos |
| ES2453941T5 (es) | 2005-11-30 | 2017-05-31 | Abbvie Inc. | Anticuerpos monoclonales contra la proteína beta amiloide y usos de los mismos |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| US9403902B2 (en) | 2007-10-05 | 2016-08-02 | Ac Immune S.A. | Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody |
| EP2558494B1 (en) | 2010-04-15 | 2018-05-23 | AbbVie Inc. | Amyloid-beta binding proteins |
| NZ606357A (en) | 2010-07-30 | 2015-05-29 | Genentech Inc | Safe and functional humanized anti beta-amyloid antibody |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| CA2850531C (en) * | 2011-09-29 | 2016-06-07 | Cellsnap, Llc | Compositions and methods for toxigenicity testing |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2072356A1 (en) * | 1989-12-29 | 1991-06-30 | James L. Urban | Diagnosis and treatment of diseases |
| US5216132A (en) * | 1990-01-12 | 1993-06-01 | Protein Design Labs, Inc. | Soluble t-cell antigen receptor chimeric antigens |
| JPH06507384A (ja) * | 1991-01-22 | 1994-08-25 | ザ イミューン レスポンス コーポレイション | 特定のｔ細胞群による病理的応答により生じる疾患に対するワクチン投与および方法 |
| US5480895A (en) * | 1991-09-27 | 1996-01-02 | New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery | Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof |
| US5891623A (en) * | 1992-11-09 | 1999-04-06 | Consorzio Per Le Biotecnologie | Diagnosis and treatment of AIDS onset |
| US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| US5589328A (en) * | 1994-08-04 | 1996-12-31 | Mahant; Vijay K. | Chemiluminescence assays based on indoxyl substrates, thioindoxyl substrates and other substrates |
-
1998
- 1998-07-20 IL IL13327798A patent/IL133277A0/xx active IP Right Grant
- 1998-07-20 TR TR2000/00181T patent/TR200000181T2/xx unknown
- 1998-07-20 CA CA2296842A patent/CA2296842C/en not_active Expired - Fee Related
- 1998-07-20 SI SI9830782T patent/SI0998556T1/xx unknown
- 1998-07-20 KR KR1020007000632A patent/KR100567277B1/ko not_active IP Right Cessation
- 1998-07-20 EP EP05076378A patent/EP1595951A1/en not_active Withdrawn
- 1998-07-20 DK DK98935160T patent/DK0998556T3/da active
- 1998-07-20 US US09/463,158 patent/US6689359B1/en not_active Expired - Fee Related
- 1998-07-20 EP EP98935160A patent/EP0998556B1/en not_active Expired - Lifetime
- 1998-07-20 JP JP50949099A patent/JP2002511765A/ja not_active Ceased
- 1998-07-20 NZ NZ501424A patent/NZ501424A/en not_active IP Right Cessation
- 1998-07-20 PT PT98935160T patent/PT998556E/pt unknown
- 1998-07-20 WO PCT/GB1998/002151 patent/WO1999005175A2/en active IP Right Grant
- 1998-07-20 DE DE69830588T patent/DE69830588T2/de not_active Expired - Lifetime
- 1998-07-20 PL PL338449A patent/PL204503B1/pl not_active IP Right Cessation
- 1998-07-20 CN CNB988073803A patent/CN1330754C/zh not_active Expired - Fee Related
- 1998-07-20 AT AT98935160T patent/ATE297983T1/de active
- 1998-07-20 KR KR1020057007380A patent/KR100670070B1/ko not_active IP Right Cessation
- 1998-07-20 ES ES98935160T patent/ES2245034T3/es not_active Expired - Lifetime
- 1998-07-20 EA EA200000146A patent/EA003131B1/ru not_active IP Right Cessation
- 1998-07-20 BR BR9810118-8A patent/BR9810118A/pt not_active Application Discontinuation
- 1998-07-20 AU AU84517/98A patent/AU758455B2/en not_active Ceased
-
1999
- 1999-12-02 IL IL133277A patent/IL133277A/en not_active IP Right Cessation
-
2000
- 2000-01-18 CU CU20000009A patent/CU23412A3/es not_active IP Right Cessation
-
2003
- 2003-10-01 US US10/674,433 patent/US20050100541A1/en not_active Abandoned
-
2006
- 2006-05-31 IL IL176076A patent/IL176076A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL176076A0 (en) | Ligands,including antibodies showing, reactivity against endocrine cells | |
| BR0112602A (pt) | Compostos e métodos para tratamento e diagnóstico de infecção clamidial | |
| ATE283289T1 (de) | Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten | |
| DE59705683D1 (de) | IMMUNOLOGISCHES NACHWEISVERFAHREN VON ANTIKÖRPERN, DIE GEGEN GEWEBE-TRANSGLUTAMINASE (tTG) GERICHTET SIND, VERWENDUNG VON tTG ZUR DIAGNOSE UND THERAPIEKONTROLLE SOWIE ORALES PHARMAZEUTISCHES MITTEL ENTHALTEND tTG | |
| NO973447D0 (no) | Monoklonale antistoffer som er spesifikke for forskjellige epitoper i human-gp 39, og fremgangsmåter for deres anvendelse i diagnose og terapi | |
| Isersky et al. | Immunochemical cross-reactions of human amyloid proteins with human immunoglobulin light polypeptide chains | |
| DK161015C (da) | Blanding til anvendelse ved ekstern paavisning og lokalisering af en blodprop | |
| BR0016066A (pt) | Compostos e métodos para tratamento e diagnóstico de infecção clamidial | |
| WO2003086308A3 (en) | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection | |
| RU2004126238A (ru) | Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro | |
| RU2012120706A (ru) | Диагностические и терапевтические способы | |
| ATE442439T1 (de) | Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren | |
| DE69840509D1 (de) | Apoptose-bezogene verbindungen und deren verwendung | |
| ATE244299T1 (de) | Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis | |
| WO1995017425A3 (en) | Markers of organ rejection | |
| HUP9901688A2 (hu) | A diabétesz kezelésére szolgáló, humán hősokk protein 60-ból származó új peptidek, készítmények, eljárások és kitek | |
| NO960858L (no) | Anvendelser av myelin - oligodendrocyt-glykoprotein og peptid-deler derav i metoder i forbindelse med autoimmunsykdom | |
| DK0687180T3 (da) | Fremgangsmåde til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-anti | |
| NO962596L (no) | Nytt tumorsupressorgen | |
| WO1999021994A3 (en) | Human vesicle membrane protein-like proteins | |
| Levo et al. | Diagnosis and classification of arnyloidosis by an immuno-histological method | |
| CA2140091A1 (en) | Peptides and antisera for detecting human cyclooxygenase-1 and cyclooxygenase-2 | |
| DK1254374T3 (da) | Fremgangsmåde til diagnose af effektiviteten ved xenotype-antistofbehandling | |
| WO2003020108A3 (en) | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection | |
| WO1998041538A3 (en) | Novel human cytokine/steroid receptor protein |